Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

DBCOND0069346Hemic and Lymphatic Diseases Immune System Diseases

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is the indication for 2 drugs in DrugBank. It is covered by 3 curated, structured indications.

Also known as: Blastic plasmacytoid dendritic cell neoplasia · Blastic Plasmacytoid Dendritic Cell Neoplasm · BPDCN
Classified under: Hemic and Lymphatic Diseases
Immune System Diseases
Neoplasms
Skin and Subcutaneous Tissue Diseases
Indicated drugs: Pivekimab sunirine
Tagraxofusp

Resolves to

Vocabularies

MeSHM000767994ICD-10C86.4SNOMED CT397354007MedDRA10075460UMLSC1301363

What you can answer from here — as of October 16, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

41Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account